4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks Investment Research9/21/2026Positive
BIIB
Biogen IncNASDAQHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$33.63B
P/E Ratio
40.72
EPS
$5.59
Beta
0.17
52W High
$229.19
52W Low
$135.39
50-Day MA
$212.58
200-Day MA
$193.71
Dividend Yield
—
Profit Margin
8.32%
Forward P/E
13.95
PEG Ratio
2.35
About Biogen Inc
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Fundamentals
| Revenue (TTM) | $10.03B |
| Gross Profit (TTM) | $7.85B |
| EBITDA | $3.36B |
| Operating Margin | 25.10% |
| Return on Equity | 4.58% |
| Return on Assets | 5.21% |
| Revenue/Share (TTM) | $68.19 |
| Book Value | $127.61 |
| Price-to-Book | 1.78 |
| Price-to-Sales (TTM) | 3.35 |
| EV/Revenue | 4.058 |
| EV/EBITDA | 19.02 |
| Quarterly Earnings Growth (YoY) | -84.80% |
| Quarterly Revenue Growth (YoY) | 3.40% |
| Shares Outstanding | $147.75M |
| Float | $147.22M |
| % Insiders | 0.19% |
| % Institutions | 99.50% |
Historical Volatility
HV 10-Day
20.44%
HV 20-Day
26.50%
HV 30-Day
27.26%
HV 60-Day
36.78%
HV Rank
15.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($238.18 target)
3
Strong Buy20
Buy11
Hold1
SellLatest News
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).
GlobeNewsWire9/17/2026Neutral
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease
GlobeNewsWire9/16/2026Neutral
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.
MarketBeat9/15/2026Positive
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
Zacks Investment Research9/8/2026Positive
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines –
GlobeNewsWire9/3/2026Neutral
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease
GlobeNewsWire9/3/2026Neutral
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
GlobeNewsWire9/1/2026Neutral
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
GlobeNewsWire8/31/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIIB and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026